Literature DB >> 21893489

Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria.

Johannes M Douwes1, Rosa L E van Loon, Elke S Hoendermis, Anton Vonk-Noordegraaf, Marcus T R Roofthooft, Melle D Talsma, Hans L Hillege, Rolf M F Berger.   

Abstract

AIMS: To assess the occurrence and prognostic value of acute vasodilator response (AVR) in paediatric vs. adult pulmonary arterial hypertension, and idiopathic/hereditary pulmonary arterial hypertension (iPAH/HPAH) vs. pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) using three different response criteria. METHODS AND
RESULTS: Ninety-nine PAH patients underwent AVR testing (37 children, 62 adults; 70 iPAH/HPAH, 29 PAH-CHD). Three response criteria from clinical practice were used to define AVR. The number of responders was evaluated separately in subgroups based on age, diagnosis, and presence of a non-restrictive post-tricuspid shunt. Numbers of responders varied importantly using the different criteria but were always higher in iPAH/HPAH, compared with PAH-CHD. The number of responders did not differ between paediatric and adult iPAH/HPAH. No responders were identified in patients with a post-tricuspid shunt. Acute vasodilator response was associated with improved survival using all three criteria. Low baseline mean right atrial pressure (mRAP) was associated with improved survival in adults (P< 0.001). High baseline mean pulmonary arterial pressure (mPAP)/mean systemic arterial pressure (mSAP) and pulmonary vascular resistance (PVR)/systemic vascular resistance (SVR) were associated with worse survival, statistically independent from age, diagnosis, and the presence of a post-tricuspid shunt.
CONCLUSION: The proportion of patients with AVR highly depends on the used criteria, but did not differ between paediatric and adult iPAH/HPAH. Current response criteria are not suitable for patients with a post-tricuspid shunt. In both children and adults without post-tricuspid shunts, AVR was associated with improved survival independent of the used criteria. Nevertheless, prognostic value in the individual patient was limited. Baseline mRAP showed a good correlation with survival for adult PAH patients, but not for children. High baseline mPAP/mSAP and PVR/SVR was associated with worse prognosis independent from age, diagnosis, or the presence of a post-tricuspid shunt.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21893489     DOI: 10.1093/eurheartj/ehr282

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  22 in total

Review 1.  Treatment of pulmonary arterial hypertension in children.

Authors:  Heiner Latus; Tammo Delhaas; Dietmar Schranz; Christian Apitz
Journal:  Nat Rev Cardiol       Date:  2015-02-03       Impact factor: 32.419

2.  Pulmonary Arterial Capacitance Is an Important Predictor of Mortality in Heart Failure With a Preserved Ejection Fraction.

Authors:  Nadine Al-Naamani; Ioana R Preston; Jessica K Paulus; Nicholas S Hill; Kari E Roberts
Journal:  JACC Heart Fail       Date:  2015-06       Impact factor: 12.035

Review 3.  Drug treatment of pulmonary hypertension in children.

Authors:  Erika E Vorhies; David Dunbar Ivy
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

4.  Intensive Care Mortality Prognostic Model for Pediatric Pulmonary Hypertension.

Authors:  Emily Morell Balkin; Matt S Zinter; Satish K Rajagopal; Roberta L Keller; Jeffrey R Fineman; Martina A Steurer
Journal:  Pediatr Crit Care Med       Date:  2018-08       Impact factor: 3.624

Review 5.  Progress in the diagnosis and management of pulmonary hypertension in children.

Authors:  Jeremy Nicolarsen; Dunbar Ivy
Journal:  Curr Opin Pediatr       Date:  2014-10       Impact factor: 2.856

6.  Hemodynamic Evaluation of Children with Persistent or Recurrent Pulmonary Arterial Hypertension Following Complete Repair of Congenital Heart Disease.

Authors:  Heiner Latus; Inken Wagner; Stefan Ostermayer; Gunter Kerst; Joachim Kreuder; Dietmar Schranz; Christian Apitz
Journal:  Pediatr Cardiol       Date:  2017-07-05       Impact factor: 1.655

Review 7.  Pulmonary Hypertension in Children.

Authors:  Dunbar Ivy
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

8.  Clinical classification in pediatric pulmonary arterial hypertension associated with congenital heart disease.

Authors:  Willemijn M H Zijlstra; Johannes M Douwes; Mark-Jan Ploegstra; Usha Krishnan; Marcus T R Roofthooft; Hans L Hillege; D Dunbar Ivy; Erika B Rosenzweig; Rolf M F Berger
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

9.  Acute pulmonary vasoreactivity test with sildenafil or nitric monoxide before left ventricular assist device implantation.

Authors:  Teruhiko Imamura; Koichiro Kinugawa; Masaru Hatano; Naoko Kato; Shun Minatsuki; Hironori Muraoka; Toshiro Inaba; Hisataka Maki; Mitsutoshi Kimura; Osamu Kinoshita; Taro Shiga; Atsushi Yao; Shunei Kyo; Minoru Ono; Issei Komuro
Journal:  J Artif Organs       Date:  2013-04-05       Impact factor: 1.731

Review 10.  Drug Treatment of Pulmonary Hypertension in Children.

Authors:  Catherine M Avitabile; Erika E Vorhies; David Dunbar Ivy
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.